Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects

As obesity evolves as a global pandemic, the use of drugs to treat it is booming. The latest among these are Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Along with their use, the incidence of adverse events has become more common. Although severe effects have been mentioned, details and a...

Full description

Bibliographic Details
Published in:Endocrines
Main Authors: Pranjal Sharma, Venkata Buddhavarapu, Gagandeep Dhillon, Ram Kishun Verma, Ramprakash Devadoss, James Raynor, Ripudaman Munjal, Harpreet Grewal, Rahul Kashyap
Format: Article
Language:English
Published: MDPI AG 2024-08-01
Subjects:
Online Access:https://www.mdpi.com/2673-396X/5/3/23